Drug Profile
Research programme: CXCR4 inhibitors - Spexis
Alternative Names: POL3026; POL5551Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Polyphor
- Developer Polyphor; Spexis
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
- No development reported Inflammation; Stem cell mobilisation
- Discontinued HIV infections
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from preclinical studies in B cell lymphoma models at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 22 Feb 2022 Preclinical development is ongoing in Switzerland in Haematological malignancies (Parenteral) (Spexis pipeline, February 2022)
- 22 Feb 2022 Preclinical trials in Haematological malignancies in Switzerland (Parenteral) (Spexis pipeline, February 2022)